Method and system for optimizing communication in a home network via a gateway
US-9203869-B2 · Dec 1, 2015 · US
Methods and compositions for treatment of retinoid-responsive conditions
US9308239B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9308239-B2 |
| Application number | US-39333109-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 26, 2009 |
| Priority date | Feb 26, 2008 |
| Publication date | Apr 12, 2016 |
| Grant date | Apr 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject having a retinoid-responsive condition. Retinoid-responsive conditions illustratively include acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating acne in a subject, comprising: administering a therapeutically effective amount of an NGAL stimulator, wherein the NGAL stimulator is selected from the group consisting of: a Toll-like receptor 2 ligand, a Toll-like receptor 3 ligand, an activator of NFκB, leukotriene B4, cholesterol oleate and interleukin-17 (IL-17), to a subject having acne. 2. The method of claim 1 , wherein the activator of NFκB is selected from the group consisting of: interleukin 1-beta (IL1-beta) and tumor necrosis factor-alpha (TNF-alpha). 3. The method of claim 1 , wherein the Toll-like receptor 2 ligand is N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-N-lysyl-[S]-lysyl-[S]-lysine. 4. The method of claim 1 , wherein the Toll-like receptor 3 ligand is polyinosinic:polycytidylic acid. 5. The method of claim 1 , wherein the NGAL stimulator is administered to skin affected by acne in the subject.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Antibacterial agents · CPC title
- A61K38/20Primary
Interleukins [IL] · CPC title
Antipsoriatics · CPC title
Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9308239B2 cover?
- Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject…
- Who is the assignee on this patent?
- Thiboutot Diane, Nelson Amanda, Lumsden Kimberly, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/20. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).